Alzheimer's Disease Clinical Trials in Massachusetts

58 recruiting studies across 1 city

Browse by City

All Trials in Massachusetts

Phase

Trial	Phase	Sponsor	Dist.
Dominantly Inherited Alzheimer Network (DIAN)	—	Washington University School of Medicine	<1 mi
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	<1 mi
Longitudinal Early-onset Alzheimer's Disease Study Protocol	—	Indiana University	<1 mi
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies	Phase 3	Hoffmann-La Roche	<1 mi
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)	Phase 3	Karuna Therapeutics, Inc., a Bristol Myers Squibb company	<1 mi
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	<1 mi
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease	Phase 2	Lighthouse Pharmaceuticals, Inc.	<1 mi
Biomarker-based Trial of NPC-1 for Alzheimer's Pathology	Phase 2	Massachusetts General Hospital	<1 mi
Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia	N/A	Hebrew SeniorLife	<1 mi
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)	Phase 1/2	AC Immune SA	<1 mi
Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)	—	University of Pennsylvania	<1 mi
Cognitive Neurology Unit Clinical Registry	—	Beth Israel Deaconess Medical Center	<1 mi
A Study To Assess The Feasibility Of Indivi Mobile Application In Monitoring Cognitive Performance In Aging Population	—	Indivi AG	<1 mi
TMS for Cognitive Decline in Aging and Preclinical AD	N/A	Massachusetts General Hospital	<1 mi
Improving Memory in Alzheimer's Disease With Noninvasive Brain Stimulation	N/A	Boston University Charles River Campus	<1 mi
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	Phase 3	Hoffmann-La Roche	<1 mi
Mindfulness for Cognition in Early-stage Alzheimer's Disease	N/A	VA Boston Healthcare System	<1 mi
Gamma-Music Based Intervention for Mild Alzheimer's Disease	N/A	Northeastern University	<1 mi
Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD	—	Massachusetts General Hospital	<1 mi
Trial to Reduce Antimicrobial Use in Nursing Home Residents With Alzheimer's Disease and Other Dementias 2.0	N/A	Hebrew SeniorLife	<1 mi
Triage Survey for Neurology Research Eligibility	—	Adams Clinical	<1 mi
Transcranial Magnetic Stimulation Treatment for Alzheimer's Disease	Early 1	Massachusetts General Hospital	<1 mi
Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain Function in Alzheimer's Disease	N/A	Boston University Charles River Campus	<1 mi
Assess Fibrin in Brains With AD/ADRD	Phase 1/2	Massachusetts General Hospital	<1 mi
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia	Phase 2	Intra-Cellular Therapies, Inc.	<1 mi
Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People at Risk for Alzheimer's Disease	N/A	Massachusetts General Hospital	<1 mi
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease	Phase 2	Brigham and Women's Hospital	<1 mi
Contributions of mTBI to Neurodegeneration Due to Chronic Traumatic Encephalopathy (CTE) and Alzheimer's Disease (AD)	—	VA Office of Research and Development	<1 mi
Trial-Ready Cohort-Down Syndrome (TRC-DS)	—	University of Southern California	<1 mi
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant	Phase 3	Eidos Therapeutics, a BridgeBio company	<1 mi
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases	Phase 1/2	Brigham and Women's Hospital	<1 mi
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)	Phase 2	Eli Lilly and Company	1 mi
Individual Closed-Loop Neuromodulation Therapy for Alzheimer's Disease	N/A	Massachusetts General Hospital	1 mi
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease	Phase 1	Eli Lilly and Company	1 mi
Gamma Frequency Stimulation in Individuals With Down Syndrome	N/A	Massachusetts Institute of Technology	3 mi
Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices)	Phase 2	Massachusetts Institute of Technology	3 mi
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy	N/A	Massachusetts Institute of Technology	3 mi
Home-Based Brain Stimulation for Motoric Cognitive Risk Syndrome	N/A	Hebrew SeniorLife	6 mi
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease	Phase 1/2	AbbVie	6 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)	Phase 3	Bristol-Myers Squibb	6 mi
Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside	—	Mclean Hospital	7 mi
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)	N/A	Brent Forester	7 mi
The BRAIN App (Phase 2 SBIR)	N/A	Hopeful Aging	8 mi
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease	Phase 3	Bristol-Myers Squibb	8 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)	Phase 3	Bristol-Myers Squibb	8 mi
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)	Phase 3	Bristol-Myers Squibb	8 mi
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)	Phase 2	Merck Sharp & Dohme LLC	8 mi
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).	Phase 3	Eli Lilly and Company	8 mi
[18F]PI-2620 Phase 3 Histopathological Study	Phase 3	Lantheus Biosciences Ltd.	11 mi
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease	Phase 2	Novartis Pharmaceuticals	26 mi
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)	Phase 3	Bristol-Myers Squibb	39 mi
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type	Phase 2	Teikoku Pharma USA, Inc.	39 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease	Phase 2	Celgene	41 mi
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia	—	GAP Innovations, PBC	41 mi
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Phase 2/3	Washington University School of Medicine	41 mi
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Phase 2/3	Washington University School of Medicine	41 mi
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD	Phase 1	Butler Hospital	41 mi
Clinical Trial on Agitation in Alzheimer's Dementia	Phase 2	IGC Pharma, LLC	41 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.